Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

FirstWord Pharma
firstwordpharma.com > story > 7984983

WCLC26: GSK's ris-rez cuts death risk 54% in China Phase III lung cancer trial

15+ hour, 6+ min ago   (16+ words) FirstWord Pharma...

firstwordpharma.com
firstwordpharma.com > story > 7973027

Friday Five??? Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal???and more

3+ day, 6+ hour ago   (19+ words) Friday Five – Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal…and more firstwordpharma.com...

FirstWord PHARMA
firstwordpharma.com > story > 7972807

Takeda's R&D head Andy Plump to retire after back-to-back approvals

3+ day, 8+ hour ago   (13+ words) FirstWord PHARMA...

FirstWord PHARMA
firstwordpharma.com > story > 7969054

Schr??dinger forms I&I-focused newco with NEA, RA Capital

4+ day, 4+ hour ago   (11+ words) Schrödinger forms I&I-focused newco with NEA, RA Capital FirstWord PHARMA...

FirstWord Pharma
firstwordpharma.com > story > 7963969

Inhibrx touts HNSCC subgroup data, eyes accelerated pathway for OX40 agonist

5+ day, 6+ hour ago   (13+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7965266

Physician Views Preview: How are prescribing patterns changing in COPD?

5+ day, 1+ hour ago   (12+ words) FirstWord Pharma...

FirstWord PHARMA
firstwordpharma.com > story > 7961783

Amgen claims win for Imdelltra in maintenance lung cancer setting

5+ day, 12+ hour ago   (12+ words) FirstWord PHARMA...

FirstWord Pharma
firstwordpharma.com > story > 7960102

Roivant's pulmonary hypertension drug mosliciguat scores mid-stage win

5+ day, 20+ hour ago   (10+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7959810

Novartis??? Avidity-sourced del-desiran stumbles in Phase III myotonic dystrophy study

5+ day, 22+ hour ago   (12+ words) Novartis’ Avidity-sourced del-desiran stumbles in Phase III myotonic dystrophy study FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7957772

Physician Views Preview: Can AstraZeneca's Etcamah carve out a new treatment paradigm in breast cancer?

6+ day, 17+ hour ago   (17+ words) FirstWord Pharma...